Welcome to the
Galenica network.
Our ambition is to meet the needs of patients and customers in the Swiss healthcare market in a seamless, efficient and personalised way. To achieve this, we operate the Galenica network with over 20 Business Units, the strongest partners in the Swiss healthcare market.
Half year report 2024: A strong network for Switzerland
Despite the challenging market environment in the first half of 2024, we achieved solid sales growth of 2.6% and thus gained market shares.
Perspectives in the Galenica network
Galenica reports strong sales growth once again
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors
Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual General Meeting of the Galenica Group.
Patrick Rindlisbacher and Martin Recknagel now jointly manage Medifilm
This top-sharing approach allows the two co-managers to make the best possible use of their respective expertise and thus prepare Medifilm for the next phase of growth.
Corporate
Information
Galenica (SIX Swiss Exchange)
79.90 CHF
Volume
15,570.00
01/24/2025 10:18
«We have embedded our network philosophy even more firmly into our strategy. Clients will benefit from a comprehensive range of services from a single source.»